Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia

PHASE3CompletedINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

July 2, 2014

Primary Completion Date

March 19, 2016

Study Completion Date

March 19, 2016

Conditions
Alopecia
Interventions
DRUG

Dutasteride

Dutasteride will be supplied as soft gelatin capsules, containing 0.5 mg of dutasteride to be administered orally.

DRUG

Placebo

Dutasteride matching placebo will be supplied as capsules to be administered orally.

Trial Locations (18)

106

GSK Investigational Site, Taipei

169608

GSK Investigational Site, Singapore

7580206

GSK Investigational Site, Santiago

Unknown

GSK Investigational Site, Pokfulam

GSK Investigational Site, Shatin

GSK Investigational Site, Chungcheongnam-do

GSK Investigational Site, Taipei

301-721

GSK Investigational Site, Daejeon

501-757

GSK Investigational Site, Gwangju

463-707

GSK Investigational Site, Gyeonggi-do

400-711

GSK Investigational Site, Incheon

561-712

GSK Investigational Site, Jeonju-si, Jeollabuk-do

220-701

GSK Investigational Site, Kangwon-Do

602-739

GSK Investigational Site, Pusan

110-744

GSK Investigational Site, Seoul

134-090

GSK Investigational Site, Seoul

143-729

GSK Investigational Site, Seoul

156-755

GSK Investigational Site, Seoul

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Stiefel, a GSK Company

INDUSTRY